Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
The Pharmaceutical Market: Spain
Management Report
Published: January 2010
Pages: 108
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 595.00 Buy Now!
Research from: Espicom
Sector: Prescription Medicines
Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
The Spanish pharmaceutical market is the fifth largest in the EU-27. Pharmacy sales are growing at a slower rate compared to hospital sales, but they still represent about three quarters of the market at manufacturers’ prices. In spite of the economic crisis, sales of prescription-only medicines (POM) are performing well, as most of them are prescriptions for the elderly and therefore subsidised. Sales of over-the-counter (OTC) medicines, however, have been affected by the economic slowdown and increasing competition between pharmacies and other establishments.
Economic deterioration is expected in Spain in 2010. The effects of the crisis on the pharmaceutical industry are tangible, as the crisis obliges pharmaceutical companies to prioritise R&D, streamline employment and improve competitiveness. Some international companies with subsidiaries in Spain have decided to cut their personnel or close their plants, but overall the National Pharmaceutical Association (FARMAINDUSTRIA) has negotiated a plan for the sector with the Ministries of Health, Industry and Science & Innovation.
In the last two years, the industry has responded well to a more relaxed regulatory market environment, with a stable reference pricing system, therefore it has invested more in R&D. The draft of the 2009-2012 Profarma programme, presented in June 2009, aims to take into account not only R&D investments but also production capabilities, which might affect companies which only have R&D capabilities in Spain. The objectives highlighted by the draft are aligned with the agreement signed between FARMAINDUSTRIA and the government in March 2009.
In June 2009, the Ministry of Health, the region of Andalusia and ROVI signed an agreement to build a vaccine manufacturing centre in Granada, Andalusia. This will be the first centre for the production of vaccines against normal and pandemic flu in Spain, and the ninth in Europe. The manufacturing plant is expected to be fully operational in 2012. Investments amount to 60.0 million euros (US$79.4 million), most of which will be invested by ROVI. The new plant will employ about 250 people.
Highly detailed report content
MARKET OUTLOOK
Key national data projections
Pharmaceutical Market Analysis
Current market size
Market structure
Unique 5-year market projections
Imports
Domestic manufacturing
Exports
Research & development
Pharmaceutical regulatory analysis
Including regulation, pricing & reimbursement and intellectual property
Pharmaceutical distribution
Healthcare analysis
Including demographics, healthcare system, health expenditure, healthcare infrastructure and personnel HEALTHCARE DATA
A comprehensive tabula review of the market, including economic indicators, demographics, health expenditure, hospital and primary care data, and healthcare personnel.
Economic deterioration is expected in Spain in 2010. The effects of the crisis on the pharmaceutical industry are tangible, as the crisis obliges pharmaceutical companies to prioritise R&D, streamline employment and improve competitiveness. Some international companies with subsidiaries in Spain have decided to cut their personnel or close their plants, but overall the National Pharmaceutical Association (FARMAINDUSTRIA) has negotiated a plan for the sector with the Ministries of Health, Industry and Science & Innovation.
In the last two years, the industry has responded well to a more relaxed regulatory market environment, with a stable reference pricing system, therefore it has invested more in R&D. The draft of the 2009-2012 Profarma programme, presented in June 2009, aims to take into account not only R&D investments but also production capabilities, which might affect companies which only have R&D capabilities in Spain. The objectives highlighted by the draft are aligned with the agreement signed between FARMAINDUSTRIA and the government in March 2009.
In June 2009, the Ministry of Health, the region of Andalusia and ROVI signed an agreement to build a vaccine manufacturing centre in Granada, Andalusia. This will be the first centre for the production of vaccines against normal and pandemic flu in Spain, and the ninth in Europe. The manufacturing plant is expected to be fully operational in 2012. Investments amount to 60.0 million euros (US$79.4 million), most of which will be invested by ROVI. The new plant will employ about 250 people.
Highly detailed report content
MARKET OUTLOOK
Key national data projections
Pharmaceutical Market Analysis
Current market size
Market structure
Unique 5-year market projections
Imports
Domestic manufacturing
Exports
Research & development
Pharmaceutical regulatory analysis
Including regulation, pricing & reimbursement and intellectual property
Pharmaceutical distribution
Healthcare analysis
Including demographics, healthcare system, health expenditure, healthcare infrastructure and personnel HEALTHCARE DATA
A comprehensive tabula review of the market, including economic indicators, demographics, health expenditure, hospital and primary care data, and healthcare personnel.